$279.00
+1.6%BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
ONC • NASDAQ
| BeOne Medicines Ltd. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
286.9M | -644.8M | -881.7M | -2B | -1.4B | -1.6B | -950.6M | -674M | -93.3M | -119.2M | -57.1M | -18.5M | -7.9M | |
141.7M | 171.8M | 87.7M | 66.3M | 46.5M | 31.8M | 18.6M | 10.4M | 4.8M | 1.9M | 1.5M | 1.6M | 1.6M | |
9.5M | 26M | 689K | 2.1M | -41.1M | -27.8M | -9.2M | -21.9M | -5.8M | 2.9M | 2.1M | -70K | -112K | |
510.9M | 441.6M | 367.6M | 303.2M | 240.7M | 183.5M | 134.2M | 87.1M | 42.9M | 10.6M | 10.2M | 6.6M | -24K | |
-12.8M | 22M | -361.2M | 3.3M | -13.1M | -21M | 67.6M | 68M | 7.1M | 121K | 1.1M | 3.3M | 2.8M | |
(0.0) | (69.4M) | (56M) | (29.5M) | (15.7M) | (10.6M) | (9M) | (12K) | (29.3M) | (25K) | (0.0) | (0.0) | (0.0) | |
191.4M | -157.2M | -370.5M | 132.4M | -118.3M | 150.6M | -10.8M | -17.2M | 57.2M | 14.1M | 2.3M | -1.5M | 7.7M | |
1.1B | -140.6M | -1.2B | -1.5B | -1.3B | -1.3B | -750.3M | -547.7M | 12.8M | -89.5M | -39.8M | -8.7M | 4.1M | |
INVESTING ACTIVITIES | |||||||||||||
-185.8M | -492.7M | -561.9M | -469.1M | -314.9M | -229M | -158.6M | -140.8M | -58.7M | -23.5M | -5.3M | -654K | -264K | |
(0.0) | (0.0) | (0.0) | -1.4B | (51.9M) | (109.5M) | (69M) | (70.6M) | (19.9M) | (0.0) | (0.0) | -2.4M | (0.0) | |
-11.8M | -19M | -14.9M | -17.4M | -2.2B | -5.7B | -1.2B | -2.6B | -741.3M | -382.1M | -119.3M | -30.6M | (0.0) | |
3.4M | 2.7M | 673.2M | 1.6B | 3.1B | 2.8B | 1.9B | 2.2B | 423.8M | 183.7M | 65.7M | 102K | 0.0 | |
-81.9M | -39.3M | -36.4M | 1.4B | -51.9M | -109.5M | -69M | -108.9M | -329.9M | 4K | 1K | -30.5M | 14K | |
-276.2M | -548.4M | (60M) | (1.1B) | (640.7M) | -3.2B | (554.2M) | -637.6M | -356.3M | -221.8M | -58.9M | -33.6M | -250K | |
FINANCING ACTIVITIES | |||||||||||||
196.8M | 0.0 | 0.0 | 0.0 | 3.4B | 4.2B | 0.0 | 1.6B | 339.1M | 368.9M | 0.0 | 0.0 | 0.0 | |
889.7M | 145.1M | 360.8M | -65.9M | 101.5M | 289.6M | 34.7M | 33.6M | 132.8M | 12M | 5.9M | 17.8M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -75K | -80K | (0.0) | |
-27.1M | 48.4M | 55.7M | 47M | 92.8M | 681.2M | 51M | 29.7M | 18.5M | -23K | 77K | -1.1M | -482K | |
1.1B | 193.4M | 416.5M | -19M | 3.6B | 5.2B | 85.7M | 1.7B | 490.4M | 380.9M | 103.2M | 52.2M | -482K | |
CASH FLOW SUMMARY | |||||||||||||
60M | -51.7M | -8.1M | -69.4M | 14M | 18.2M | -9.5M | -4.1M | 5.3M | 104K | -485K | 142K | -41K | |
2B | -547.2M | -689.1M | -507.9M | 3B | 769.2M | -119.9M | 501.1M | 152.1M | 69.6M | 4M | 10M | 3.3M | |
2.6B | 3.2B | 3.9B | 4.4B | 1.4B | 620.8M | 740.7M | 239.6M | 87.5M | 17.9M | 13.9M | 3.9M | 626K | |
4.6B | 2.6B | 3.2B | 3.9B | 4.4B | 1.4B | 620.8M | 740.7M | 239.6M | 87.5M | 17.9M | 13.9M | 3.9M | |
941.7M | -669.8M | -1.8B | -2B | -1.6B | -1.5B | -908.9M | -688.6M | -46M | -113M | -45.2M | -9.3M | 3.8M |
ONC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 14, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 17, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 19, 2025 | November 13, 2025 | 2025 |
Continue your ONC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.